Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-21 receptor subunit alpha (IL-21R, also known as CD360) is a type I cytokine receptor subunit that forms a functional heterodimeric complex with the common gamma chain (IL-2RG) to bind and transduce signals for interleukin-21 (IL-21). It is predominantly expressed on the surface of immune cells, including T cells, B cells, natural killer (NK) cells, and dendritic cells. Upon ligand binding, IL-21R recruits and activates Janus kinases JAK1 and JAK3, which subsequently phosphorylate and activate STAT3, STAT1, and STAT5 transcription factors, driving immune cell proliferation, differentiation, and effector functions.
The IL-21/IL-21R axis plays a dual role in human pathology: overactivation is associated with autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), while its activation is critical for anti-tumor immunity and viral clearance. Consequently, therapeutic strategies target this receptor in two opposing ways: IL-21R antagonists (such as the monoclonal antibody ATR-107) are developed to suppress aberrant immune responses in autoimmunity, whereas IL-21R agonists (such as denenicokin, latikafusp, and ANV700) are designed to boost cytotoxic T cell and NK cell activity in cancer immunotherapy. However, clinical development has faced challenges, including high immunogenicity and hypersensitivity reactions for antagonists, and systemic toxicities or immune exhaustion for agonists.
Interleukin-21 receptor antagonist, Interleukin-21 receptor agonist, Activation of JAK/STAT signaling pathway, Inhibition of IL-21/IL-21R signaling pathway
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-21 receptor subunit alpha (IL-21R).